Safety, Tolerability, and Immunogenicity of mRNA-1325 in Healthy Adult Subjects

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-12-21

Study Completion Date

2019-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The clinical study will assess the safety, tolerability, and immunogenicity of mRNA-1325 in healthy adult subjects.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Ad26.ZIKV.001 in Healthy Adult Volunteers

NCT03356561

Healthy

COMPLETED PHASE1

Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults

NCT06334393

Zika Zika Virus Infection

ACTIVE_NOT_RECRUITING PHASE1

Study Evaluating Safety And Tolerability Of Meningococcal B Rlp2086 Vaccine In Healthy Adults

NCT00879814

Meningitis, Meningococcal

COMPLETED PHASE1

Immunogenicity, Safety and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recominant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Toddlers.

NCT02534935

Meningococcal B Disease

COMPLETED PHASE2

A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

NCT01352793

Meningitis, Meningococcal

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Zika Virus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

mRNA-1325

Group Type EXPERIMENTAL

mRNA-1325

Intervention Type BIOLOGICAL

Escalating dose levels

Placebo

0.9% sodium chloride

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

mRNA-1325

Escalating dose levels

Intervention Type BIOLOGICAL

Placebo

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 to 49 years of age
* Body mass index between 18 and 35 kg/m2
* In good health as determined by medical history
* Female subjects must be non pregnant and non lactating and meet one of the following criteria: a) post menopausal b) surgically sterile
* Women of childbearing potential must agree to be heterosexually inactive or agree to consistently use any of the following methods of contraception from at least 21 days prior to enrollment and through 3 months after the final vaccination
* Male subjects must use an acceptable method of birth control throughout the entire study and agree to refrain from donation of sperm from the time of first vaccination until 3 months following the last vaccination
* Agrees to comply with the study procedures and provides written informed consent
* Has access to a consistent and reliable means of telephone contact and agrees to stay in contact with the study site for the duration of the study, to provide updated contact information as necessary, and has no current plans to move from the study area for the duration of the study

Exclusion

* Any ongoing, symptomatic acute or chronic illness requiring medical or surgical care
* A history of active cancer (malignancy) in the last 10 years
* Female of childbearing potential and has a positive pregnancy test at screening or on the day of vaccination
* Administration of an investigational product within 60 days, or 5 half-lives, whichever is longer
* Administration of any live attenuated vaccines within 4 weeks before enrollment or inactive vaccines within 2 weeks before enrollment, or plans to receive any vaccine during the active vaccination period
* Prior administration of a vaccine for Zika or dengue vaccine, a history of confirmed Zika or dengue infection, or has lived in or visited any Zika-endemic area greater than 4 weeks in duration
* Prior administration of investigational agent using formulations similar to mRNA-1325
* A history of hypersensitivity or serious reactions to previous vaccinations
* Any known or suspected autoimmune disease or immunosuppressive condition, acquired or congenital, as determined by medical history and/or physical examination
* A history of inflammatory arthritis
* Any neurologic disorder
* A history of febrile disease with arthritis or arthralgia within 2 weeks of dose administration.
* Prior administration of immunoglobulins and/or any blood products within the 3 months preceding the administration of the study drug or plans to receive such products at any time during the study
* Any chronic administration of an immunosuppressant or other immune modifying drug
* Any acute illness at the time of enrollment
* Any significant disorder of coagulation requiring ongoing or intermittent treatment
* A history of idiopathic urticaria
* A history of alcohol abuse or drug addiction
* A positive test result for drugs of abuse
* The subject has any abnormality or permanent body art (eg, tattoo) that, in the opinion of the investigator, would obstruct the ability to observe local reactions at the injection site
* Any condition that, in the opinion of the investigator, would pose a health risk to the subject if enrolled or could interfere with evaluation of the study drug or interpretation of study results
* A positive test result for hepatitis B surface antigen, hepatitis C virus antibody, or human immunodeficiency virus types 1 or 2 antibodies
* Donation of blood or blood products \> 450 mL within 30 days of dosing.
* Abnormal vital signs or screening safety laboratory test results including liver enzyme tests
* Is an employee or first degree relative of the Sponsor, CRO, or study site personnel

Minimum Eligible Age

18 Years

Maximum Eligible Age

49 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes